Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02576353 · ClinicalTrials.gov registry record · Phase 1

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

A Phase 1 study of Pharmacokinetics and Pharmacodynamics, sponsored by INSYS Therapeutics.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT02576353: Completed Phase 1 study of Pharmacokinetics and Pharmacodynamics, sponsored by INSYS Therapeutics.

NCT02576353 is a Phase 1 study of Pharmacokinetics and Pharmacodynamics that has completed, run by INSYS Therapeutics. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02576353, a Phase 1 study of Pharmacokinetics and Pharmacodynamics, has completed, sponsored by INSYS Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to determine the pharmacokinetic and pharmacodynamic relationship of a single dose of fentanyl sublingual spray in opioid naive subjects. The secondary objective is to determine the safety and tolerability of fentanyl sublingual spray in opioid naive subjects.

Interventions

  • DRUG Fentanyl Citrate
  • DRUG Fentanyl

Study Locations (1)

California

  • Lotus Clinical Research - Pasadena

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2015-10
Est. Completion 2015-11
Phase Phase 1
INSYS Therapeutics

35 total trials

What the finished NCT02576353 record still lists

NCT02576353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).

The record links to 1 condition, with Pharmacokinetics and Pharmacodynamics appearing as the primary indexed condition, and to 2 interventions - of which Fentanyl Citrate is the first listed.

NCT02576353 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02576353 about?

NCT02576353 is a clinical study titled "Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects". The primary objective of this study is to determine the pharmacokinetic and pharmacodynamic relationship of a single dose of fentanyl sublingual spray in opioid naive subjects. The secondary objective is to determine the safety and tolerability of fentanyl sublingual spray in opioid naive subjects.

What is the current status of trial NCT02576353?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-10. Estimated completion is 2015-11.

What conditions does trial NCT02576353 study?

This clinical trial studies the following conditions: Pharmacokinetics and Pharmacodynamics.

What interventions are being tested in trial NCT02576353?

The interventions under investigation include: Fentanyl Citrate (DRUG), Fentanyl (DRUG).

Who is sponsoring clinical trial NCT02576353?

This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02576353 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics and Pharmacodynamics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02576353's enrollment target sits among peer trials

50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02576353, the US trial registry maintained by the National Library of Medicine. NCT02576353 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.